Targeting US$610 billion longevity market, biotech firms race to reverse ageing
Biotech firms are using AI to chase longevity therapies, with METiS TechBio pitching cell reprogramming and nano-delivery platforms for ageing-related disease.
Intelligence analysis by GPT-5.4 Mini
The article frames longevity as a fast-moving biotech race in which AI is speeding up how firms model biology and design therapies. Beijing-based METiS TechBio is presented as one of the companies trying to turn that research into a business, backed by a Hong Kong IPO and major investors.
A biotech company is trying to use computers and tiny medicine carriers to fix cells as they get old, like repairing broken parts in a machine before the whole thing slows down.
Analysis
The pitch
Beijing-based METiS TechBio is presenting ageing as a systems problem: once errors accumulate in cells, the body’s functions decline. Its CEO says AI could help read, rewrite and even partially reverse those changes, or at least slow them down.
What the company is building
The start-up says it uses AI to design nano-delivery platforms that can carry drug payloads to specific cells and organs. One focus mentioned in the article is immune cells such as T cells, whose function weakens with age and leaves older people more vulnerable to cancer and other diseases.
Why the field is drawing attention
The piece says cellular reprogramming has become one of the most ambitious areas in longevity science, and AI is accelerating the way biotech firms model human biology and search for treatments. The article also notes that the United States remains the global leader in this space, helped by large private investment and R&D, and it cites Longevity Technology data showing the U.S. accounts for 57% of longevity companies and 84% of deal volume.
The business angle
The market opportunity is large enough to attract serious capital. METiS raised US$269.5 million in a Hong Kong IPO on May 13, with BlackRock and UBS Asset Management Singapore among the cornerstone investors. The article frames this as part of a broader race to capture a longevity market it values at US$610 billion.
Bottom line
The story is less about a proven anti-ageing cure than about a commercial push to turn early-stage science into platform technology, investment, and future therapies.
Key points
- METiS TechBio says AI can help design therapies that slow or reverse ageing at the cellular level.
- The company focuses on nano-delivery platforms that send drug payloads to specific cells and organs.
- Its CEO argues that ageing starts with accumulated errors in cells and could be partly reprogrammed.
- The article says the U.S. remains the global leader in longevity investment and company share.
- METiS raised US$269.5 million in a Hong Kong IPO, with BlackRock and UBS Asset Management Singapore as cornerstone investors.
If the technology works, AI could help scientists find better ways to target ageing-related problems and make treatments more precise. The company could also use that approach to build a stronger business around health and longevity tools.
The article makes clear that the field is still early, so the science may not move from promise to real treatments quickly. The market is crowded and the U.S. already leads, which could make it hard for newer entrants to catch up.
